As previously announced on February 6, given the pending acquisition of Nevro (NVRO) by Globus Medical, Nevro is not issuing FY25 guidance, nor is the company holding an earnings conference call ...

Nevro has a beta of 0.91 ... HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion ...

Nevro Corp. NVRO reported a loss per share of 64 cents in the fourth quarter of 2024, wider than the year-ago quarter’s loss of 15 cents. The Zacks Consensus Estimate is pegged at a loss per ...